SY-001 by CellOrigin Technology (Hangzhou) for Solid Tumor: Likelihood of Approval

SY-001 is under clinical development by CellOrigin Technology (Hangzhou) and currently in Phase I for Solid Tumor.

Tropical Parasite May Be Endemic in Texas

A parasitic disease that can cause skin ulcers and is usually spread by the tiny sandfly may now be endemic to the U.S., preliminary findings

October 24, 2023

Floatation therapy may be a novel treatment for anorexia nervosa

A trailblazing study conducted by researchers at the Laureate Institute for Brain Research (LIBR) in Tulsa, Okla., has made significant strides with a novel technique

August 30, 2023

Medline pulls thousands of endotracheal tubes due to risk of airway blockage

Listen to the article 2 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: Medline has asked hospitals to

June 13, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.